←Back to Expert Scholars
Translational Medicine / 转化医学STING Agonist Trials, Early Phase IO
Jason J. Luke
MD
🏢UPMC Hillman Cancer Center🌐USA
Director, Cancer Immunotherapeutics Center
68
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jason Luke leads early-phase STING agonist and novel IO combination trials, including pivotal studies of intratumoral and systemic STING agonists designed to convert cold tumors. He has developed the T cell inflamed gene expression profile as a biomarker for cold-to-hot conversion strategies.
Share:
🧪Research Fields 研究领域
STING agonist clinical trials
phase 1 immunotherapy
neoantigen biomarkers
combination IO strategy
T cell inflamed signature
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jason J. Luke 的研究动态
Follow Jason J. Luke's research updates
留下邮箱，当我们发布与 Jason J. Luke（UPMC Hillman Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment